Candesartan: Nephroprotective effects and treatment of diabetic nephropathy

Drugs of Today

Volumn 39, Issue 6, 2003, Pages 439-450

  Mimran, Albert ^a   Alfaro, Vicente ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; TELMISARTAN; VALSARTAN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE MEASUREMENT; CELL PROTECTION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY CELL; KIDNEY FAILURE; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RANDOMIZATION; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTEMIC DISEASE; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; TETRAZOLES;

EID: 0041431069     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.6.799449     Document Type: Review

References (75)

1. Remuzzi, G., Schieppati, A., Ruggenenti, P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346: 1145-51.
2. Tobe, S.W., McFarlane, P.A., Naimark, D.M. Microalbuminuria in diabetes mellitus. CMAJ 2002, 167: 499-503.
3. Ritz, E. Nephropathy in type 2 diabetes. J Intern Med 1999, 245: 111-26.
4. Ritz, E., Orth, S.R. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999, 341: 1127-33.
5. Ordonez, J.D., Hiatt, R.A. Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population. Nephron 1989, 51: 524-9.
6. Vora, J.P., Ibrahim, H.A., Bakris, G.L. Responding to the challenge of diabetic nephropathy: The historic evolution of detection, prevention and management. J Hum Hypertens 2000, 14: 667-85.
7. Bakris, G.L., Williams, M., Dworkin, L. et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36: 646-61.
8. Sowers, J.R., Bakris, G.L. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000, 342: 969-70.
9. Wolf, G., Butzmann, U., Wenzel, U.O. The Renin-Angiotensin system and progression of renal disease: From hemodynamics to cell biology. Nephron 2003, 93: P3-P13.
10. Unger, T. Pharmacological properties of angiotensin II antagonists: Examining all the therapeutic implications. J Renin Angiotensin Aldosterone Syst 2001, 2 (Suppl. 2): S4-7.
11. Guo, D.F., Sun, Y.L., Hamet, P., Inagami, T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 2001, 11: 165-80.
12. Navar, L.G., Harrison-Bernard, L.M. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res 2000, 23: 291-301.
13. Navar, L.G., Harrison-Bernard, L.M., Nishiyama, A., Kobori, H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002, 39: 316-22.
14. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345: 870-8.
15. Mogensen, C.E., Neldam, S., Tikkanen, I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321: 1440-4.
16. Wheeldon, N., Viberti, G., for the MARVAL Trial. Microalbuminuria reduction with valsartan. Am J Hypertens 2001, 14: 2A.
17. Ichikawi, I., Harris, R.C. Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int 1991, 40: 583-96.
18. Imanishi, M., Yoshioka, K., Konishi, Y. et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999, 42: 999-1005.
19. Andersen, S., Blouch, K., Bialek, J., Deckert, M., Parving, H.H., Myers, B.D. Glomerularpermselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000, 58: 2129-37.
20. Bonnet, F., Cooper, M.E., Kawachi, H., Allen, T.J., Boner, G., Cao, Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001, 44:874-7.
21. Andersen, S., Tarnow, L., Rossing, P., Hansen, B.V., Parving, H.H. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57: 601-6.
22. Wolf, G., Ziyadeh, F.N. The role of angiotensin II in diabetic nephropathy: Emphasis on non-hemodynamic mechanisms. Am J Kidney Dis 1997, 29: 153-63.
23. Lewis, E.J., Hunsicker, L.G., Clarke, W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-60.
24. Brenner, B.M., Cooper, M.E., de Zeeuw, D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-9.
25. Ruddy, M.C. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens 2002, 15: 468-71.
26. Ramahi, T.M. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. Postgrad Med 2001, 109: 115-22, quiz 9.
27. Morsing, P. Candesartan: A new-generation angiotensin II AT1 receptor blocker. Pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 1999, 10 (Suppl. 11:) S248-54.
28. Morsing, P., Adler, G., Brandt-Eliasson, U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999, 33: 1406-13.
29. Gavras, H. Update on the clinical pharmacology of candesartan cilexetil. Am J Hypertens 2000, 13: 25S-30S.
30. Asmar, R., Lacourciere, Y. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000, 18: 1683-90.
31. Lansang, M.C., Osei, S.Y., Price, D.A., Fisher, N.D., Hollenberg, N.K. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000, 36: 834-8.
32. Gleiter, C.H., Morike, K.E. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002, 41: 7-17.
33. Buter, H., Navis, G.Y., Woittiez, A.J., de Zeeuw, D., de Jong, P.E. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 1999, 54: 953-8.
34. Noda, M., Matsuo, T., Nagano-Tsuge, H. et al. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). Jpn J Pharmacol 2001, 85: 416-22.
35. Taal, M.W., Chertow, G.M., Rennke, H.G. et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol (Renal Physiol) 2001, 280: F343-55.
36. Griffin, K.A., Picken, M.A., Bakris, G., Bidani, A.K. Relative antihypertensive and glomerulo-protective efficacies of enalapril and candesartan ciletexil in the remnant kidney model. J Renin Angiotensin Aldosterone Syst 2001, 2: S191-S195.
37. Allen, T.J., Cao, Z., Youssef, S., Hulthen, U.L., Cooper, M.E. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997, 46: 1612-8.
38. Nabokov, A., Amann, K., Gassmann, P., Schwarz, U., Orth, S.R., Ritz, E. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998, 13: 173-6.
39. Cervenka, L., Heller, J., Jelinek, F. Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Kidney Blood Press Res 1996, 19: 241-4.
40. Baylis, C., Mitruka, B., Deng, A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992, 90: 278-81.
41. Casellas, D., Benahmed, S., Artuso, A., Jover, B. Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 1999, 10 (Suppl. 11): S230-3.
42. Jover, B., Mimran, A. Nitric oxide inhibition and renal alterations. J Cardiovasc Pharmacol 2001, 38 (Suppl. 2): S65-70.
43. Fridman, K.U., Elmfeldt, D., Wysocki, M., Friberg, P.R., Andersson, O.K. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Press 2002, 11: 244-52.
44. Elmfeldt, D., Olofsson, B., Meredith, P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002, 11: 293-301.
45. Kawabata, M., Takabatake, T., Ohta, H. et al. Effects of an angiotensin II receptor antagonist, TC V-116, on renal haemodynamics in essential hypertension. Blood Press 1994, 5: 117-21.
46. Fridman, K., Andersson, O.K., Wysocki, M., Friberg, P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 1997, 11 (Suppl. 2): S43-4.
47. Hollenberg, N.K., Price, D.A., Fisher, N.D., et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003, 63: 172-8.
48. Rossing, K., Christensen, P.K., Hansen, B.V., Carstensen, B., Parving, H.H. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study. Diabetes Care 2003, 26: 150-5.
49. Berger, E.D., Bader, B.D., Ebert, C., Risler, T., Erley, C.M. Reduction of proteinuria, combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002, 20: 739-43.
50. Nussberger, J., Brunner, D.B., Waeber, B., Brunner, H.R. Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens 1985, 3 (Suppl. 3): S269-70.
51. Hollenberg, N.K., Fisher, N.D., Price, D.A. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32: 387-92.
52. Remuzzi, A., Gagliardini, E., Donadoni, C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002, 62: 885-94.
53. Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329: 1456-62.
54. Jacobsen, P., Andersen, S., Jensen, B.R., Parving, H.H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14: 992-9.
55. Kurokawa, K. Effects of candesartan on the proteinuria of chronic glomerulonephritis. J Hum Hypertens 1999, 13 (Suppl. 1): S57-60, discussion S61.
56. Segura, J., Campo, C., Nieto, J. et al. Positive simultaneous effect of candesartan dose up-titration on proteinuria and blood pressure. In: American Society of Hypertension 2003, submittted.
57. Weinberg, M.S., Weinberg, A.J., Cord, R., Zappe, D.H. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst 2001, 2: 196-198.
58. Weinberg, A.J., Haneiwich, R., Weinberg, M.S. The safety and efficacy of supramaximal doses of candesartan cilexetil (160 mg) in chronic renal disease patients naïve to angiotensin receptor blockade therapy. In: American Sociey of Hypertension (ASH) Annual Scientific Meeting 2003, Abstr. 152.
59. Trenkwalder, P., Lehtovirta, M., Dahl, K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or.serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997, 11 (Suppl. 2): S81-3.
60. Caruso, S., D'Isanto, F., Maglione, B. et al. Candesartan vs. amlodipine in double blind study in hypertensive patients with diabetic nephropathy. J Hypertens 2000, 18: S153.
61. Lansang, M.C., Price, D.A., Laffel, L.M. et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001, 59: 1432-8.
62. Hebert, L.A., Falkenhain, M.E., Nahman, N.S., Jr., Cosio, F.G., O'Dorisio, T.M. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999, 19: 1-6.
63. Azizi, M., Guyene, T.T., Chatellier, G., Wargon, M., Menard, J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997, 29: 634-40.
64. Russo, D., Pisani, A., Balletta, M.M. et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999, 33: 851-6.
65. Zoccali, C., Valvo, E., Russo, D., Panichi, V., Zuccala, A. Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant 1997, 12: 234-5.
66. Rossing, K., Christensen, P.K., Jensen, B.R., Parving, H.H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care 2002, 25: 95-100.
67. Jacobsen, P., Andersen, S., Rossing, K., Hansen, B.V., Parving, H.H. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002, 17: 1019-24.
68. Luno, J., Barrio, V., Goicoechea, M.A. et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002, 62 (Suppl. 82): 47-52.
69. Trenkwalder, P. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press Suppl 2000, 1: 27-30.
70. Belcher, G., Hubner, R., George, M., Elmfeldt, D., Lunde, H. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997, 11 (Suppl 2): S85-9.
71. Kincaid-Smith, P., Fairley, K., Packham, D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002, 17: 597-601.
72. Freudenthaler, S.M., Schreeb, K., Korner, T., Gleiter, C.H. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999, 29: 816-23.
73. Hansen, H.P., Rossing, P., Tarnow, L., Nielsen, F.S., Jensen, B.R., Parving, H.H. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995, 47: 1726-31.
74. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002, 25 (Suppl. 1): S1-147.
75. Christensen, P.K., Lund, S., Parving, H.H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001, 60: 1435-42.